Home > Insider Trading > Filing (0000899243-22-035785)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1403752	Zymeworks Bc Inc.	ZYME	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1864141	Neil Josephson	C/O Zymeworks Inc. 108 Patriot Drive, Suite A Middletown DE 19709	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-11-10	5,885	$0.00	16,924	No	4	M	Direct
Common Stock	Disposition	2022-11-10	2,475	$8.10	14,449	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Restricted Stock Unit	Disposition	2022-11-10	5,885	$0.00	5,885	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
11,772			No	4	M	Direct

Footnotes

Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on November 10, 2021.
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs. Pursuant to the terms of the applicable RSU grant agreement (the "Grant Agreement"), effective on the grant date of the RSUs, the Reporting Person adopted a 10b5-1 plan pursuant to which the Reporting Person elected to sell shares to cover tax withholding obligations and other applicable fees in accordance with the terms of the Grant Agreement.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.09 to $8.10, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
The RSUs were granted on November 10, 2021 and vest in three equal annual instalments beginning on November 10, 2022.